The frequency and mean titer of anti-skeletal muscle (SM) antibody in myasthenic patients with thymoma (64 cases) were significantly high (frequency, 92%; mean titer, 10.1) in all stages of severity, while in myasthenic patients without thymoma (202 cases), they were significantly low (frequency, 24%; mean titer, 2.2). A strong association was found in myasthenic patients between the occurrence of anti-SM antibodies and the presence of thymoma. No correlation was found between titers of anti-SM antibody and those of anti-acetylcholine receptor (AChR) antibody (r=0.036), although myasthenic patients with thymoma had simultaneously high prevalences of anti-AChR (62/64) and anti-SM (59/64) antibodies. Most of the ocular mysthenic patients with and without thymoma had no or extremely low anti-AChR antibody titers (frequency, 25%, 16/65; mean titer, 1.6pmol/ml). Whereas, in all cases of ocular myasthenic patients with thymoma anti-SM antibodies were significantly high titers (frequency, 100%, 8/8; mean titer, 11.0). Reductions in both anti-AChR and anti-SM antibody titers were observed by the serial measurement after thy(mo)mectomy on most of the 10 myasthenic patients with thymoma.Our data on a large number of myasthenic sera reveal that coexistence of anti-SM and anti-AChR antibodies is strongly linked to myasthenia gravis associated with thymoma. The measurement of anti-SM antibodies is recommended for demonstration of thymoma in myasthenic patients before surgery.
No takes yet. Share an insight, caveat, or question.
Ohta et al. (1989) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: